The biopharmaceutical sector has witnessed significant changes in leadership roles within major Contract Development and Manufacturing Organizations (CDMOs), driving strategic growth and development. The appointment of seasoned leaders plays a crucial role in strengthening the research,
Artis Biosolutions' acquisition of Landmark Bio marks a strategic move designed to bolster cell and gene therapy (CGT) manufacturing capabilities. Landmark Bio, founded by Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva, has been a key player
The recent resignation of Peter Marks as the head of the FDA's Center for Biologics Evaluation and Research (CBER) marks a significant moment for the cell and gene therapy industry. His departure has sparked widespread discussion about the future direction of the regulatory landscape and its
Epic Medical, headquartered in Singapore, is poised to significantly impact Pekin, Illinois, by investing $25 million in a new medical equipment manufacturing facility. Announced during a well-attended news conference in the Pekin City Council meeting room, the agreement was formalized by Mayor
In a groundbreaking initiative aimed at transforming the health regulatory landscape across the African continent, the first African Regulators Leadership Program (ARLP) was convened at the Wits Business School in Johannesburg. This program is designed to elevate the leadership skills and
In a surprising move, Sutro Biopharma has decided to undertake a sweeping restructuring plan with the primary goal of conserving capital, leading to a nearly 50% reduction in its workforce, the ousting of CEO Bill Newell, the discontinuation of its lead drug candidate luveltamab tazevibulin